Beta-thalassemia, Glioma, Healthy Controls, Intracranial Hemorrhages, Toxicity, Transfusion-dependent Beta-Thalassemia
Conditions
Keywords
Plasticizer, Transfusion, Systems Biology, Immunology, Microbiome, Neuropharmacology, Pharmacokinetics, Pharmacodynamics, Exposomics
Brief summary
Plasticizers are chemicals commonly found in many everyday items, from food packaging to medical equipment. Although they are pervasive in our daily lives, researchers still don't have a clear picture of their long-term effects on human health. Evidence suggests that these substances might disrupt various biological functions such as the immune system, the balance of gut bacteria, hormone regulation, and brain processes. While some studies have linked plasticizer exposure to health issues, definitive data from human studies are still lacking. The PEACH study aims to bridge these knowledge gaps by investigating how plasticizers affect human health. The study focuses on understanding how these chemicals are absorbed, distributed, and accumulated in the body across different groups of patients. The investigators are particularly interested in how plasticizers influence gut microbiota and the functionality of immune cells, as well as their effects on neurotransmitters involved in brain function. A combination of patient data, systems biology, and laboratory models will be used to thoroughly assess the biological impacts of plasticizers. Advanced techniques such as mass spectrometry will aid in studying toxicokinetic properties, sequencing technologies will be used to examine immune effects, and radiouptake assays will be employed to explore interactions with neurotransmitter transport. This comprehensive methodology will provide new insights into the effects of both short-term and long-term exposure to plasticizers. The PEACH study introduces innovative methods to the field, aiming to create a robust model for understanding how plasticizer compounds behave in the human body. It employs state-of-the-art techniques to assess the dynamics of these chemicals, marking a significant advancement in environmental health research.
Detailed description
Wider research context: Industrial plasticizers are ubiquitous in modern society, utilized in products ranging from food packaging to medical supplies. Despite their widespread use, the health implications of chronic plasticizer exposure in humans remain inadequately understood. These substances potentially interfere and disrupt various biological processes, including immune activity, gut microbiota balance, endocrinological function, and neurophysiological health. Current epidemiological or exposure studies were able to pinpoint clinical associations with plasticizer exposures, but conclusive mechanistic human in vivo data are missing. Research questions: The PEACH study is designed to fill critical gaps in the understanding of the biological implications of plasticizer exposure. The investigators aim to analyse the pharmacokinetics of plasticizers in different patient cohorts and elucidate their bioaccumulation, distribution, and metabolism. Thereby, the interplay between plasticizer exposure and metabolism, gut microbiota composition and immune cell functionality will be explored. Furthermore, the impact of plasticizer exposure on neurotransmitter physiology will be elucidated. Approach: The study employs a comprehensive methodology that integrates the findings from clinical cohorts, systems biology approaches, and in vitro models. Three distinct work packages will examine pharmacokinetic properties via mass spectrometry, study immunological effects through advanced sequencing technologies & phenotypization, and investigate pharmacodynamic interactions with neurotransmitter transporters using human in-vitro assays. Longitudinal sampling from acute and chronic exposure cohorts will offer an evolving perspective on effects of plasticizer exposure. Level of originality: The PEACH study introduces groundbreaking methodologies and scope to the investigation of plasticizer exposure. It aims to support the scientific community with first human in-vivo pharmacokinetic models for these compounds while utilizing high-throughput techniques for pharmacodynamic assessment, marking a notable advancement in the field.
Interventions
None listed
Sponsors
University of Vienna
Medical University of Vienna
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
TDTM: * Inclusion: Adult, homozygous ß-Thalassemia Major, transfusion dependency. * Exclusion: Plastic implants, chronic infectious disease, pregnancy. Thalassemia Intermedia/Minor: * Inclusion: Adult, homozygous/heterozygous ß-Thalassemia Intermedia/Minor * Exclusion: Plastic implants, chronic infectious disease, pregnancy, transfusion dependency Healthy adults: * Inclusion: Adult * Exclusion: Chronic disease, plastic implants, infectious disease, pregnancy, anemia, medication-, drug-, or alcohol-abuse Glioma patients: * Inclusion: Adult, high/low-grade glioma, tumor larger then 3cm, resection with access to the ventricular system * Exclusion: Large intraventricular hemorrhage, plastic implants, infectious disease ICU patients: * Inclusion: Adult, brain hemorrhage, external CSF drain from ventricle * Exclusion: intraventricular hemorrhage, plastic implants, ECMO, hemodialysis, infectious disease Patients undergoing diagnostic lumbar-puncture: * Inclusion: Adult, diagnostic CSF sampling, outpatient setting * Exclusion: Ventricular hemorrhage, plastic implants, infectious disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accumulation of plasticizers in transfused patients | 3 years | Plasticizer concentrations (mmol/L) will be measured from the plasma of thalassemia major patients two weeks after the last pRBC-transfusion and compared to plasma levels of healthy controls of beta-thalassemia intermedia/minor patient using MANCOVA. Age, sex and liver/kidney retention will be taken into account as covariates and Tukey HSD or Scheffe tests used for even and uneven group sizes, respectively. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Accumulation of plasticizers during storage in pRBC-bags | 1 year | Biweekly measurements of blood-bag aliquots will be conducted, and concentrations of \> 30 plasticizer analyzed. 15 of these (main compounds) will be used and subjected to repeated measures ANOVA with within group comparisons. The Sidak correction will be used as a post-hoc test. |
| Plasticizer release into the CSF of ICU-patients | 3 years | The accumulation/release of plasticizers within/into the CSF (mmol/L) will be monitored longitudinally in relation to time (h) using repeated-measures ANCOVA with Sidak correction. Age, sex, as well as liver and kidney function will be considered as covariates. |
| Studying the accumulation of plasticizers within the CSF using a cross-sectional design | 3 years | Accumulation of plasticizers within CSF will be analyzed using MANCOVA, taking age, sex, liver/kidney function as covariates. Thereby, abundancy (mmol/L) of plasticizers within the CNS will be compared between groups. |
| Pharmacodynamic analyses (IC50) | 3 years | IC50 (mmol/L) values for neurotransmitter transport at SLC6 transporters will be derived upon co-incubation with plasticizers during the uptake of the transporters cognat substrate to describe the pharmacological profile of plasticizers and their interaction with neurotransmitter transport. |
| Pharmacodynamic analyses (Vmax) | 3 years | Vmax values for neurotransmitter transport at SLC6 transporters (pmol/min) will be derived upon co-incubation with plasticizers during the uptake of the transporters cognat substrate to describe the pharmacological profile of plasticizers and their interaction with neurotransmitter transport. |
Countries
Austria
Contacts
Primary ContactLukas Wisgrill, MD, PhD
Backup ContactHarald Sitte, MD, PhD
Outcome results
None listed